AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20473745 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI) given to the observation group for 14 days along with basic treatment including polarized liquid therapy.
Number of subjects: 64
Study 20473745 — intervention group
Group type: COMPARATOR
Intervention: Control group received basic treatment including polarized liquid therapy without SMI.
Number of subjects: 64
Study 18712038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily for 12 months
Number of subjects: 30
Study 18712038 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily for 12 months
Number of subjects: 30
Study 15969859 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 375
Study 15969859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 12874080 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course clindamycin (3 doses)
Number of subjects: 74
Study 12874080 — intervention group
Group type: COMPARATOR
Intervention: Long-course clindamycin (15 doses)
Number of subjects: 74
Study 10477009 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 66
Study 8945129 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vaginal douche for one day (Group A)
Number of subjects: 31
Study 8945129 — intervention group
Group type: COMPARATOR
Intervention: Daily vaginal douche for four days (Group B)
Number of subjects: 31
Study 1901543 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 200
Study 1901543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 200
Study 1901543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 200
Study 1901543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 200
Study 7072756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 9
Study 7072756 — intervention group
Group type: COMPARATOR
Intervention: Control preparation (starch or saccharin)
Number of subjects: 9
Study 30312423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 240
Study 30312423 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 240
Study 30312423 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 240
Study 28315479 — intervention group
Group type: EXPERIMENTAL
Intervention: personalized pharmaceutical and psychological education
Number of subjects: 0
Study 28315479 — intervention group
Group type: EXPERIMENTAL
Intervention: personalized pharmaceutical and general education
Number of subjects: 0
Study 28315479 — intervention group
Group type: COMPARATOR
Intervention: placebo pharmaceutical and psychological education
Number of subjects: 0
Study 26364968 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF)
Number of subjects: 83
Study 26364968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine (DK)
Number of subjects: 83
Study 24372314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular irrigation and betamethasone injection (group I)
Number of subjects: 30
Study 24372314 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment and rigid maxillomandibular fixation (MMF) (group II)
Number of subjects: 30
Study 22024157 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot wound infiltration of 20mL of ropivacaine 7.5mg/mL (Group R; n=56)
Number of subjects: 100
Study 22024157 — intervention group
Group type: COMPARATOR
Intervention: Single-shot wound infiltration of 20mL of saline solution (Group T; n=44)
Number of subjects: 100
Study 22024157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (R and T)
Number of subjects: 100
Study 19681340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 20
Study 19681340 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA) 100% peels
Number of subjects: 20
Study 17172557 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 6%
Number of subjects: 12
Study 17172557 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 8%
Number of subjects: 12
Study 17172557 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill inclination (0%-8%)
Number of subjects: 12
Study 15851340 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic rectilinear (BR) waveform shocks (50, 75, 100, 120, 150, 200 J)
Number of subjects: 188
Study 15851340 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic truncated exponential (BTE) waveform shocks (50, 70, 100, 125, 150, 200, 300, 360 J)
Number of subjects: 188
Study 15851340 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BR and BTE waveforms
Number of subjects: 188
Study 19728887 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mcg darbepoetin alfa every three weeks (Q3W)
Number of subjects: 705
Study 19728887 — intervention group
Group type: COMPARATOR
Intervention: 2.25 mcg/kg darbepoetin alfa weekly (QW)
Number of subjects: 705
Study 10598754 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical SPF 4 sunscreen
Number of subjects: 17
Study 10598754 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical SPF 10 sunscreen
Number of subjects: 17
Study 10598754 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical SPF 10 sunscreen
Number of subjects: 17
Study 10598754 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin layer of chemical SPF 10 sunscreen
Number of subjects: 17
Study 10598754 — intervention group
Group type: COMPARATOR
Intervention: Irradiated unprotected skin
Number of subjects: 17
Study 7562168 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet tidal breathing (end-tidal inspiration and end-tidal expiration)
Number of subjects: 49
Study 1745709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 0
Study 1745709 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 20 mg
Number of subjects: 0
Study 1745709 — intervention group
Group type: COMPARATOR
Intervention: Cocaine 40 mg
Number of subjects: 0
Study 1745709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 1745709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6192751 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVB (Cyclophosphamide, Adriamycin, Vincristine, Bleomycin) scheduled regime
Number of subjects: 54
Study 6192751 — intervention group
Group type: COMPARATOR
Intervention: CAVB (Cyclophosphamide, Adriamycin, Vincristine, Bleomycin) unscheduled regime
Number of subjects: 54
Study 6192751 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVBP (CAVB with Cis-platinum)
Number of subjects: 54
Study 31444692 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBracelet (real stimulation month)
Number of subjects: 25
Study 31444692 — intervention group
Group type: COMPARATOR
Intervention: Sham month (control)
Number of subjects: 25
Study 29398233 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% superdiluted atropine eyedrops
Number of subjects: 200
Study 29398233 — intervention group
Group type: COMPARATOR
Intervention: Control group without treatment
Number of subjects: 200
Study 24330320 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led group education program
Number of subjects: 80
Study 24330320 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet only (Control)
Number of subjects: 80
Study 24946226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate mouthwash
Number of subjects: 101
Study 24946226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin mouthwash
Number of subjects: 101
Study 24946226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 101
Study 22832261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal low-antigen-content split inactivated vaccine
Number of subjects: 54
Study 22832261 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular standard-dose inactivated split vaccine
Number of subjects: 54
Study 19582577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-administered abdominal pressure
Number of subjects: 103
Study 19582577 — intervention group
Group type: COMPARATOR
Intervention: Assistant-administered abdominal pressure
Number of subjects: 103
Study 18989229 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IFN‐gamma responses to HCMV (>500 spot‐forming units)
Number of subjects: 75
Study 18989229 — intervention group
Group type: COMPARATOR
Intervention: Weak IFN‐gamma responses to HCMV (<500 spot‐forming units)
Number of subjects: 75
Study 18989229 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong IFN‐gamma responses to HCMV
Number of subjects: 75
Study 16242586 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended advice (clinician advice + telephone-based counseling)
Number of subjects: 100
Study 16242586 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (clinician advice alone)
Number of subjects: 100
Study 12117739 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg/d)
Number of subjects: 47
Study 12117739 — intervention group
Group type: COMPARATOR
Intervention: Felodipine (5 mg/d)
Number of subjects: 47
Study 12117739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9470315 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (Group 2)
Number of subjects: 0
Study 9470315 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 100 mg (Group 3)
Number of subjects: 0
Study 9470315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 1)
Number of subjects: 0
Study 7649582 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amylin infusion
Number of subjects: 9
Study 2709497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine combined with cocaine
Number of subjects: 0
Study 2709497 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 0
Study 2709497 — intervention group
Group type: COMPARATOR
Intervention: Repeat examinations
Number of subjects: 0
Study 2709497 — intervention group
Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 0
Study 778890 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation training
Number of subjects: 3
Study 778890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 778890 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 3
Study 31317279 — intervention group
Group type: COMPARATOR
Intervention: Placebo in advanced PD patients
Number of subjects: 0
Study 28074802 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 163
Study 28074802 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional hemodynamic management)
Number of subjects: 163
Study 24935686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of ethanol/kilogram bodyweight, taken orally immediately before lights off
Number of subjects: 26
Study 23743717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 30
Study 23743717 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 30
Study 21529370 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Recognition and Treatment package (DepReT-Stroke) in addition to treatment as usual (TAU)
Number of subjects: 126
Study 21529370 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 126
Study 19195498 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg once a day
Number of subjects: 30
Study 19195498 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 40 mg once a day
Number of subjects: 30
Study 16522919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 736
Study 16522919 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 736
Study 12958326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 498
Study 12958326 — intervention group
Group type: COMPARATOR
Intervention: No TIA
Number of subjects: 498
Study 11599826 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioned group (n = 17)
Number of subjects: 35
Study 11599826 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 35
Study 9485974 — intervention group
Group type: EXPERIMENTAL
Intervention: T-bag
Number of subjects: 30
Study 9485974 — intervention group
Group type: COMPARATOR
Intervention: T-piece
Number of subjects: 30
Study 7892024 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) 4 mg administered via the L2-L3 intervertebral space
Number of subjects: 2
Study 7892024 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) 4 mg administered pre-trauma
Number of subjects: 2
Study 7892024 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2
Study 3287226 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide at a dose of 400 mg b.i.d. i.v. in 50 ml phleboclysis in 5 minutes (n = 108)
Number of subjects: 211
Study 3287226 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin at a dose of 5000 IU t.i.d. subcutaneously (n = 103)
Number of subjects: 211
Study 3287226 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 211
Study 3287226 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 211
Study 31898965 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count at baseline (per 1 × 10^9/L increase)
Number of subjects: 14231
Study 30501618 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of intravenous dexamethasone and 1 dose of normal saline (Group B)
Number of subjects: 150
Study 30501618 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of intravenous dexamethasone (Group C)
Number of subjects: 150
Study 30501618 — intervention group
Group type: COMPARATOR
Intervention: Normal saline only (Group A)
Number of subjects: 150
Study 27941394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fozivudine (FZD) 800 mg o.d., 600 mg b.i.d., 1200 mg o.d.
Number of subjects: 119
Study 27941394 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) 300 mg b.i.d.
Number of subjects: 119
Study 27941394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fozivudine (FZD)
Number of subjects: 119
Study 27941394 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 119
Study 26567086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact restorations
Number of subjects: 649
Study 26567086 — intervention group
Group type: COMPARATOR
Intervention: Defective restorations
Number of subjects: 649
Study 23827107 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection/oral itraconazole
Number of subjects: 112
Study 23827107 — intervention group
Group type: COMPARATOR
Intervention: Oral itraconazole
Number of subjects: 112
Study 21838094 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laryngectomy
Number of subjects: 20
Study 19796721 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 3242
Study 19796721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3242
Study 16631274 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (n=21)
Number of subjects: 41
Study 16631274 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (n=20)
Number of subjects: 41
Study 15571210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 4 mg/day
Number of subjects: 70
Study 15571210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15571210 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'N‐ethylcarboxamido‐adenosine (NECA)
Number of subjects: 70
Study 11731753 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 180
Study 11731753 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 180
Study 9004053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 12
Study 9004053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9114914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg) and Digoxin (0.2 mg) in combination
Number of subjects: 18
Study 9114914 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg) alone
Number of subjects: 18
Study 3678415 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspirease (IP)
Number of subjects: 13
Study 3678415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber (AC)
Number of subjects: 13
Study 3678415 — intervention group
Group type: COMPARATOR
Intervention: metered dose inhaler (MDI)
Number of subjects: 13
Study 29475008 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day (R20)
Number of subjects: 44
Study 29475008 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg/day combined with ezetimibe 10 mg/day (A10 + E10)
Number of subjects: 44
Study 27496680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg daily)
Number of subjects: 25
Study 27496680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27496680 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 25
Study 25694918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobi-C Cervical Total Disc Replacement (TDR)
Number of subjects: 245
Study 25694918 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 245
Study 22966146 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9056 400 mg/day
Number of subjects: 385
Study 22966146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 22966146 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9056 (all doses)
Number of subjects: 385
Study 20808331 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk formulation containing 975 mg of milk sphingolipids (SL)
Number of subjects: 18
Study 20808331 — intervention group
Group type: COMPARATOR
Intervention: Control formulation lacking polar milk lipids
Number of subjects: 18
Study 18454864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics for 8 days
Number of subjects: 58
Study 18454864 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 58
Study 16162706 — intervention group
Group type: COMPARATOR
Intervention: General Exercise Program (GEP)
Number of subjects: 180
Study 16162706 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually Targeted Exercise Program (ITEP)
Number of subjects: 180
Study 14551179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar 4 mg for 21 days in patients with type 2 diabetes
Number of subjects: 4
Study 14551179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar (various doses 0.5-16 mg) for healthy subjects
Number of subjects: 4
Study 14551179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragaglitazar (various doses) in healthy subjects
Number of subjects: 4
Study 11310905 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 85
Study 11310905 — intervention group
Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 85
Study 8792760 — intervention group
Group type: EXPERIMENTAL
Intervention: antidepressant treatment (amitriptyline hydrochloride, fluoxetine hydrochloride, toloxatone)
Number of subjects: 30
Study 8792760 — intervention group
Group type: COMPARATOR
Intervention: nonresponders (no treatment specified)
Number of subjects: 30
Study 8101534 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levocabastine
Number of subjects: 115
Study 8101534 — intervention group
Group type: COMPARATOR
Intervention: Orally administered terfenadine
Number of subjects: 115
Study 3299393 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone plus 0.5% potassium hydroxyquinoline sulphate cream
Number of subjects: 119
Study 3299393 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone plus 2% miconazole nitrate cream
Number of subjects: 119
Study 29076609 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based lower limb resistance training (LLRT)
Number of subjects: 47
Study 29076609 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pulmonary rehabilitation (PR) guidance + Home-based LLRT
Number of subjects: 47
Study 29076609 — intervention group
Group type: COMPARATOR
Intervention: Routine pulmonary rehabilitation (PR) guidance only
Number of subjects: 47
Study 27448679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous-to-oral solithromycin
Number of subjects: 863
Study 27448679 — intervention group
Group type: COMPARATOR
Intervention: Intravenous-to-oral moxifloxacin
Number of subjects: 863
Study 25222265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Mapping (FM)
Number of subjects: 50
Study 25222265 — intervention group
Group type: COMPARATOR
Intervention: Explicit Encoding (EE)
Number of subjects: 50
Study 22385683 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET
Number of subjects: 135
Study 22385683 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 20845217 — intervention group
Group type: EXPERIMENTAL
Intervention: Small added resistance
Number of subjects: 10
Study 20845217 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate added resistance
Number of subjects: 10
Study 20845217 — intervention group
Group type: EXPERIMENTAL
Intervention: Large added resistance
Number of subjects: 10
Study 20845217 — intervention group
Group type: COMPARATOR
Intervention: No added resistance
Number of subjects: 10
Study 18955830 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) present
Number of subjects: 100
Study 18955830 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose intolerance
Number of subjects: 100
Study 18955830 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 100
Study 18955830 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) in nondiabetic participants
Number of subjects: 100
Study 18955830 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) after adjustment for diabetes status
Number of subjects: 100